Acceleron Pharma Inc (NASDAQ:XLRN) SVP Christopher Rovaldi sold 11,000 shares of the stock in a transaction on Friday, January 12th. The stock was sold at an average price of $45.00, for a total value of $495,000.00. Following the sale, the senior vice president now directly owns 35,701 shares in the company, valued at $1,606,545. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Christopher Rovaldi also recently made the following trade(s):
- On Wednesday, January 3rd, Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock. The stock was sold at an average price of $42.42, for a total value of $96,123.72.
Shares of Acceleron Pharma Inc (XLRN) opened at $42.35 on Friday. Acceleron Pharma Inc has a 12 month low of $23.07 and a 12 month high of $46.93. The company has a market capitalization of $1,870.00, a PE ratio of -16.41 and a beta of 1.59.
Hedge funds have recently made changes to their positions in the company. Swiss National Bank boosted its stake in shares of Acceleron Pharma by 8.4% during the second quarter. Swiss National Bank now owns 50,300 shares of the biopharmaceutical company’s stock valued at $1,529,000 after purchasing an additional 3,900 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Acceleron Pharma during the third quarter valued at about $2,721,000. Fox Run Management L.L.C. boosted its stake in shares of Acceleron Pharma by 111.2% during the third quarter. Fox Run Management L.L.C. now owns 30,200 shares of the biopharmaceutical company’s stock valued at $1,127,000 after purchasing an additional 15,900 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Acceleron Pharma by 6.1% during the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after purchasing an additional 116,705 shares in the last quarter. Finally, Artisan Partners Limited Partnership acquired a new stake in shares of Acceleron Pharma during the third quarter valued at about $11,938,000. 85.70% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently issued reports on XLRN shares. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the stock a “buy” rating in a report on Tuesday, November 14th. ValuEngine lowered Acceleron Pharma from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. HC Wainwright began coverage on Acceleron Pharma in a research note on Thursday, October 12th. They issued a “buy” rating and a $57.00 price objective on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Monday, January 8th. Finally, BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $44.81.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Acceleron Pharma Inc (XLRN) SVP Sells 11,000 Shares of Stock” was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3145379/insider-selling-acceleron-pharma-inc-xlrn-svp-sells-11000-shares-of-stock.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.